Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2018 | Considerations for the long-term effects of androgen deprivation therapy

Bertrand Tombal • 16 Nov 2018
ESMO 2018
Genitourinary Cancer Prostate Cancer Abiraterone Apalutamide Enzalutamide

Bertrand Tombal, MD, PhD, of Cliniques Saint-Luc University, Brussels, Belgium, assesses the long term risks associated with androgen deprivation therapy for prostate cancer patients. Prof. Tombal speaks from the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, stressing the importance of patient monitoring and the promotion of lifestyle changes in patients to limit the effects of toxicity from the drug.

More from Bertrand Tombal

PSMA expression as a key predictor of response to PSMA lutetium therapy
1:38
PSMA expression as a key predictor of response to PSMA lutetium therapy
Bertrand Tombal • 20 Oct 2025
ENZARAD: ADT, radiotherapy and radical prostatectomy in prostate cancer
1:15
ENZARAD: ADT, radiotherapy and radical prostatectomy in prostate cancer
Bertrand Tombal • 20 Oct 2025
Emerging treatment strategies in castration-resistant prostate cancer
1:20
Emerging treatment strategies in castration-resistant prostate cancer
Bertrand Tombal • 20 Oct 2025
Optimal sequencing of therapies in metastatic prostate cancer
1:48
Optimal sequencing of therapies in metastatic prostate cancer
Bertrand Tombal • 20 Oct 2025

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals